Zacks Investment Research lowered shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a buy rating to a sell rating in a research report sent to investors on Thursday, September 20th.
According to Zacks, “KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. “
Several other research firms have also issued reports on KALV. Roth Capital initiated coverage on shares of Kalvista Pharmaceuticals in a research note on Tuesday, July 10th. They issued a buy rating and a $20.00 price objective for the company. ValuEngine raised shares of Kalvista Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, August 2nd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $24.50.
Kalvista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.14). Kalvista Pharmaceuticals had a negative net margin of 132.38% and a negative return on equity of 56.24%. The business had revenue of $3.72 million during the quarter, compared to analyst estimates of $4.11 million. Sell-side analysts expect that Kalvista Pharmaceuticals will post -1.78 earnings per share for the current year.
In other news, Director Albert Cha bought 1,058,824 shares of the business’s stock in a transaction on Monday, September 10th. The stock was purchased at an average price of $17.00 per share, with a total value of $18,000,008.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 38.40% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the business. Spark Investment Management LLC acquired a new position in Kalvista Pharmaceuticals during the 2nd quarter worth $108,000. BlackRock Inc. increased its holdings in shares of Kalvista Pharmaceuticals by 203.8% during the 2nd quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 10,871 shares during the period. DRW Securities LLC increased its holdings in shares of Kalvista Pharmaceuticals by 37.3% during the 2nd quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock worth $167,000 after purchasing an additional 5,600 shares during the period. Stanley Laman Group Ltd. increased its holdings in shares of Kalvista Pharmaceuticals by 48.3% during the 2nd quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock worth $545,000 after purchasing an additional 21,861 shares during the period. Finally, Eventide Asset Management LLC increased its holdings in shares of Kalvista Pharmaceuticals by 26.9% during the 1st quarter. Eventide Asset Management LLC now owns 900,000 shares of the specialty pharmaceutical company’s stock worth $8,532,000 after purchasing an additional 191,000 shares during the period. 36.79% of the stock is owned by hedge funds and other institutional investors.
Kalvista Pharmaceuticals Company Profile
KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.
Further Reading: Compound Annual Growth Rate (CAGR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.